Newbioideas

Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)


AMOUNT: $ 300

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March 2013 issue of Nature by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)

Significance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.

This study suggests, for the first time, a Natural product-based cardiac regeneration therapy. (+)-Syringaresinol, by increasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

Thus, by treating myocardial patients with (+)-Syringaresinol or its analogues, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “(+)-Syringaresinol or its analogues” may be used to improve cardiac function after myocardial infarction.

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To cite: Boominathan, Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 26/September/2016, 10.54 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How (+)-Syringaresinol increases the expression of PNUTS/PPP1R10

REGISTER

   

Dr.Boominathan PhD

Dr Boominathan was the first one in the world to propose a p73/p63-dependent cancer suppressor pathway (Supported by a legally valid Invention disclosure document certified by an advocate-2002/3)

Add comment

Most popular